Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

As part of Novo Holdings' takeover of pharmaceutical company Catalent last year, Novo Nordisk acquired a site in Italy along ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Investing.com -- Italian authorities appointed a special commissioner on Monday to help Novo Nordisk (NYSE: NVO) deliver its planned €2 billion ($2.34 billion) investment in a factory near Rome.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.